Page 18 - Cipla

Nifty Pharma index rallies nearly 3%; Lupin surges 10%, Cipla, Cadila up 3%

All the 10 constituents of the Nifty Pharma index were trading in the green.

Cipla tweaks management structure to mobilise second level of executives

Do these changes augur well for the future business growth plans? Analysts think so

India's supply of remdesivir is stabilising after shortages: Cipla

Cipla's launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India

Cipla hits record high on strong Q1 result; Morgan Stanley sees 30% upside

Mumbai headquartered pharma firm posted 20% growth in profit before tax for the first quarter of the current financial year to Rs 799 crore, on a 9% YoY growth in revenues to Rs 4,346 crore

'Quality' stocks come at a premium, valuations have crossed pre-Covid level

The P/E for Bharti Airtel and Avenue Supermarts is currently below the pre-Covid levels. Reliance Industries, Cipla, Havells India, and Eicher Motors have seen the maximum P/E expansion

Cipla Q1 pre-tax profit jumps 20% to Rs 799 crore on strong revenues

Firm's domestic business did well, up 16% YoY during the quarter when Cipla launched licensed version of Gilead's remdesivir

Goa coronavirus update: State to start administering remdesivir to patients

Goa's Health Ministry received 1,008 vials of Remdesivir from pharma major Cipla

Collaborating with govt agencies to develop treatment for Covid-19: Cipla

The company is offering drugs, which have shown potency in treating Covid-19, in partnership with its global partners

Cipla witnesses 3 senior-level exits including India biz CEO Nikhil Chopra

The company's rich legacy of care and strong sense of purpose rooted in a culture of meritocracy and high performance standards have made Cipla an employer of choice for several industry leaders

Big shake-up: Cipla sees 3 big exits from top management of India business

Those who have left include India business head Nikhil Chopra

Covid-19: Favipiravir triggers a price war; new brand launched at Rs 39

According to industry insiders, many more brands are lined up for launch, including one from Cipla

Cipla gets DCGI approval to sell Covid-19 drug favipiravir in India

Cipla said it would launch favipiravir as "Ciplenza" in the first week of August, priced at 68 Indian rupees (91 cents) per 200 mg tablet

Cipla, Amgen settle case involving generic cinacalcet hydrochloride tablets

Drug major Cipla said it has reached settlement with Amgen Inc on pending litigation involving generic cinacalcet hydrochloride tablets

Covid-19 treatment: A lowdown on possible cure and drugs being used

Business Standard takes a look at the common drugs that are being used in India for treating Covid-19 patients

Pharma industry steps up to cure black marketing of Covid-19 drugs

Some firms are now considering starting their own distribution centres in major cities

Cipla set to undercut rivals with low-priced generic remdesivir: Report

The drug will be available through the government and hospitals only, the company said

India's Sovereign Pharma dispatches first batch of remdesivir to Cipla

Privately held Sovereign Pharma is manufacturing and packaging Cipla's remdesivir version

Coronavirus vaccine update: Moderna vaccine trial delayed, India's by Aug15

Coronavirus vaccine latest update: A large trial of Moderna Inc's potential coronavirus vaccine has been delayed, as the company makes changes to its study plan. Catch latest updates on Covid vaccine

Cipla, Boehringer Ingelheim to co-sell 3 oral anti-diabetic drugs in India

Pharma major Cipla and drug firm Boehringer Ingelheim India on Monday announced partnership to co-market three new oral anti-diabetic drugs in the country. The companies have entered into a partnership for co-marketing three new oral anti-diabetics drugs --- Oboravo (Empagliflozin),Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin) in India, Cipla and Boehringer Ingelheim India Pvt Ltd said in a statement. As per the International Diabetes Federation, India is home to 7.7 crore diabetic adults aged between 20-79 years, ranking second behind China, and is poised to reach 13.42 crore patients by 2045, it added. "Diabetes continues to be a focus area for Cipla and with a strategic partnership with Boehringer Ingelheim coupled with our strong brand building, patient access and reach capabilities, we will be at the forefront of providing holistic diabetes care," Cipla India Business Executive VP & CEO Nikhil Chopra said. In a similar vein, Boehringer ...

Coronavirus vaccine update: AstraZeneca, Modena leading the race, says WHO

Coronavirus vaccine latest update: The University of Oxford and AstraZeneca Plc.'s experimental vaccine is the first to enter the final stages of clinical trial. Catch latest updates on Covid vaccine